Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ: PYXS ) with a Outperform and lowers the price target from $9 to $7.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.